First-in-human Safety and Immunogenicity Study of SCB-1019 and SCB-1019T in Healthy Adults

计划入组 160 人 · 首次发布于 2024 年 1 月 8 日

Vaccine Effectiveness of a Bivalent RSV Prefusion F Protein-Based Vaccine for Preventing RSV Hospitalizations in Adults

计划入组 690,000 人 · 首次发布于 2024 年 11 月 12 日

Dose, Safety, Tolerability and Immunogenicity of a Stabilized Prefusion RSV F Subunit Protein Vaccine, VRC-RSVRGP084-00-VP (DS-Cav1), Alone or With Alum Adjuvant, in Healthy Adults

计划入组 95 人 · 首次发布于 2017 年 2 月 10 日

Bivalent Respiratory Syncytial Virus prefusion F vaccine(Pfizer)(Abrysvo)

Pre F protein (GlaxoSmithKline)

RSV F protein vaccine (Novavax)

Protein Sciences Corporation

United States

Casper, Dr Robert F

Canada

Schiff, Carl F MD

United States

FDA Approves Moderna's mResvia, Third RSV Vaccine for Older Adults

Clover Advances RSV Vaccine Program with FDA Clearance for Revaccination Trial

Three RSV Vaccines Now Available for Older Adults as FDA Approves Moderna's mRESVIA